SCHEMBL2122604

SCHEMBL2122604

CS(=O)(=O)Nc1ccccc1Nc1nc(Nc2cn[nH]c2)ncc1F

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 4/20 0.70
GSK3A P49840 2/20 0.52
LRRK2 Q5S007 1/20 0.52
MAPK15 Q8TD08 1/20 0.52
CAMKK2 Q96RR4 1/20 0.52
AURKA O14965 8/20 0.48
AURKB Q96GD4 2/20 0.48
ALK Q9UM73 4/20 0.48
MAPK8 P45983 2/20 0.48
CDC7 O00311 1/20 0.48
PTK2 Q05397 2/20 0.47
PLK4 O00444 1/20 0.47
PDPK1 O15530 1/20 0.47
JAK2 O60674 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
NTRK1 P04629 1/20 0.47
INSR P06213 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2124323 0.87 ALK (0.59) GLO1LRRK2ALKPTK2JAK2
SCHEMBL1039144 0.87 GLO1 (0.83) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL656107 0.86 GLO1 (0.78) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL2123258 0.86 GLO1 (0.58) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL1039614 0.84 GLO1 (0.83) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL1040168 0.84 GLO1 (0.74) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL1707645 0.83 GLO1 (0.73) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL1037220 0.83 GLO1 (0.83) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL1037937 0.83 GLO1 (1.00) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL1039151 0.83 GLO1 (0.73) GLO1GSK3ALRRK2MAPK15CAMKK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2012-07-05 US claimed
EP-2443106-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS Cellzome Limited (GB) 2012-04-25 EP claimed
WO-2010146133-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2010-12-23 WO claimed
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2012-07-05 US disclosed
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2012-07-05 US disclosed
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2012-07-05 US disclosed
EP-2443106-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS Cellzome Limited (GB) 2012-04-25 EP disclosed
WO-2010146133-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2010-12-23 WO disclosed
WO-2010146133-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS ZAP70, JAK3, JAK2 GLO1 3371/4885GSK3A 694/4885LRRK2 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.